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Background: Pancreatic carcinoma is a significant cause of cancer-related death in developed countries. As the
level of circulating endothelial cells (CECs) is known to increase in response to various cancers, we investigated the
predictive potential of CEC levels and the association of these levels with the expression of proangiogenic factors in
pancreatic carcinoma patients.
Methods: Pancreatic carcinoma patients receiving gemcitabine chemotherapy were prospectively assigned to this
study. CEC levels were measured using the CellTracks system, and the plasma levels of several angiogenesis factors
were measured using multiplex immunoassay. Associations between clinical outcomes and the levels of these
factors were evaluated.
Results: Baseline CEC levels were markedly higher in pancreatic carcinoma patients (n = 37) than in healthy
volunteers (n = 53). Moreover, these high CEC levels were associated with decreased overall survival (median,
297 days versus 143 days, P< 0.001) and progression-free survival (median, 150 days versus 64 days, P= 0.008), as
well as with high vascular endothelial growth factor, interleukin (IL)-8, and IL-10 expression in the pancreatic
carcinoma patients.
Conclusions: Several chemokines and proangiogenic factors correlate with the release of CECs, and the number of
CECs detected may be a useful prognostic marker in pancreatic carcinoma patients undergoing gemcitabine
chemotherapy.
Trial registration: UMIN000002323
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Pancreatic carcinoma is one of the most lethal tumors
and is the fourth leading cause of cancer-related death
in developed nations [1]. As pancreatic carcinoma has a
high propensity for both local invasion and distant me-
tastasis, surgery is precluded as a treatment for most
patients who present with advanced-stage disease. These
patients have a median survival of only 6 months and an
overall 5-year survival of less than 5%. The prognosis for
advanced pancreatic carcinoma patients is therefore* Correspondence: shkondo@ncc.go.jp
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reproduction in any medium, provided the orextremely poor, and the impact of standard therapy is
only modest, despite many advances that have improved
the outcome of this disease.
Pancreatic carcinoma is not a grossly vascular tumor;
however, it overexpresses multiple mitogenic growth fac-
tors that are also angiogenic, such as epidermal growth
factor (EGF), hepatocyte growth factor (HGF), fibroblast
growth factor (FGF), platelet-derived growth factor B
chain (PDGF-BB), and vascular endothelial growth factor
(VEGF). Angiogenesis often occurs in response to an im-
balance in which proangiogenic factors predominate
over antiangiogenic factors. For instance, VEGF expres-
sion has been shown to promote tumor growth in pan-
creatic carcinomas [2]. High VEGF expression is alsoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a predictor of poor outcomes and early tumor recur-
rence after curative resection [4]. Although agents that
target the VEGF signaling pathway have been shown to
inhibit tumor growth, metastasis, and angiogenesis [5],
treating advanced pancreatic carcinoma patients with
axitinib—a selective inhibitor of VEGF receptors 1, 2,
and 3—in combination with gemcitabine was not found
to improve overall survival in a phase 3 trial [6]. Despite
this finding, proangiogenic factors remain an important
therapeutic target for the treatment of pancreatic
carcinoma.
Circulating endothelial cells (CECs) are mature cells
that are not associated with vessel walls but are detached
from the endothelium and circulate within peripheral
blood. The number of CECs present in the blood has
been found to increase in response to cardiovascular dis-
ease, vasculitis, infectious disease, and various cancers
[7,8]. Indeed, the level of CECs has been recognized as a
useful biomarker for vascular damage. It has also been
reported that the number of CECs found in non-small
cell lung cancer patients treated with carboplatin plus
paclitaxel is a promising predictive marker of the clinical
efficacy of these drugs [9]. We believe that CEC levels
may also be a potential biomarker for pancreatic carcin-
oma; therefore, we investigated the levels of CECs found
in patients with different severities of pancreatic carcin-
oma, as well as the effects of gemcitabine treatment on
CEC levels. Furthermore, the associations between CEC
levels and the expression levels of several factors
involved in angiogenesis and neovascularization were
also examined in this study.
Methods
Study approval
This prospective study was approved by the Institutional
Review Board of the National Cancer Center, and writ-
ten informed consent was obtained from all patients.
This study is registered with the University Hospital
Medical Information Network in Japan (UMIN; number
UMIN000002323) and has been completed.
Patients and blood sample collection
A total of 37 chemotherapy-naïve patients with histolo-
gically or cytologically confirmed invasive ductal pancre-
atic carcinoma were prospectively enrolled in this study
between April 2009 and March 2010 and received gem-
citabine chemotherapy. Patients with coexisting infec-
tions and/or cardiovascular illness were excluded. The
detailed history of all the patients was obtained and a
physical examination was performed before beginning
gemcitabine treatment. Pretreatment baseline laboratory
parameters were also assessed for all patients. The base-
line tumor status of each patient was evaluated usingcomputed tomography (CT) scans of the chest, abdo-
men, and pelvis, while peripheral blood sampling was
performed both prior to treatment initiation (baseline)
and at day 28 ± 7 after starting chemotherapy. A dose of
1000 mg/m2 gemcitabine was administered intraven-
ously for 30 min on days 1, 8, and 15 of a 28-day cycle
until disease progression, unacceptable toxicity, or pa-
tient refusal occurred. The data collected included those
pertaining to standard demographics and disease charac-
teristics, the date of initial treatment, the best response
to treatment, date of progression, and the date of death
or last follow-up. The tumors were evaluated every 6–
8 weeks after starting each course of gemcitabine, and
best responses were documented according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST).
CEC enumeration
Blood samples from advanced pancreatic carcinoma
patients were drawn into 10 mL CellSave Preservative
Tubes (Immunicon Corp. Huntingdon Valley, PA) for
CEC enumeration. Samples were obtained both before
starting chemotherapy (baseline) and at 28± 7 days after
starting chemotherapy. Samples were kept at room
temperature and processed within 42 h of collection. All
of the evaluations were performed without knowledge of
the clinical status of the patients. The CellTracks system
(Veridex, LLC), which consists of the CellTracks AutoP-
rep system and the CellSpotter Analyzer system, was used
for endothelial cell enumeration. In this system, CECs
are defined as CD146+/DAPI+/CD105-PE+/CD45APC-
cells. Briefly, CD146+ cells were captured immunomag-
netically by using ferrofluids coated with CD146 anti-
bodies. The enriched cells were then labeled with the
nuclear dye 4 V, 6-diamidino-2-phenylindole (DAPI),
CD105 antibodies were conjugated to phycoerythrin
(CD105-PE), and the pan-leukocyte antibody CD45 was
conjugated to allophycocyanin (CD45-APC). Cells with
the DAPI+/CD105+/CD45- phenotype were enumerated.
We evaluated morphological cell viability and excluded
dead cells from the cell count. The number of CECs in
each sample was determined twice, and the mean value
was calculated.
Antibody suspension bead array system
Peripheral blood was drawn into prechilled tubes con-
taining ethylenediaminetetraacetic acid; was immedi-
ately subjected to centrifugation at 1000 g and 4°C for
15 min, plasma was transferred to microtubes and sub-
jected to further centrifugation at 10,000 g and 4°C for
10 min to remove contaminating platelets. Plasma sam-
ples were collected from patients before gemcitabine
treatment was initiated and were stored at −80°C until
they were used for testing. The plasma concentrations
of 7 biological markers (interleukin [IL]-6, IL-8, IL-10,
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in a subgroup of patients and control individuals by
using the Bio-Plex suspension array system (Bio-Rad,
Hercules, CA), which allows the simultaneous identifi-
cation of cytokines in a 96-well filter plate. In brief, the
appropriate cytokine standards and diluted plasma sam-
ples were added to a 96-well filter plate and incubated
at room temperature for 30 min with antibodies chem-
ically attached to fluorescent-labeled micro beads. After
3 filter washes, premixed detection antibodies were
added to each well and incubated for 30 min. After 3
more washes, premixed streptavidin-phycoerythrin was
added to each well and incubated for 10 min, followed












ECOG PS 0 5
1 6
2 1
Pancreatic tumor location Head 5
Body 5
Tail 2
CA19-9 (U/mL) ≥10,000 3
< 10,000 9
CRP (mg/dL) ≥1.0 7
<1.0 5
Histology Poorly differentiated 5
Moderately differentiated 4
Adenosquamous 1
N.E (cytology only) 2
Tumor response Partial response 2
Stable disease 4
Progressive disease 6
Second line therapy S-1 6
Oxaliplatin + S-1 0
No 6
aP values were calculated for each variable using Fisher’s exact test.
Abbreviations: CEC= circulating endothelial cell; ECOG= Eastern Cooperative Oncolo125 μL of assay buffer and the reaction mixture was
quantified using the Bio-Plex protein array reader. Data
were automatically processed and analyzed with Bio-
Plex Manager Software 4.1 by using the standard curve
obtained using a recombinant cytokine standard.
Statistical analyses
The Mann–Whitney test was used to compare the distri-
butions of clinical factors and marker concentrations be-
tween patients with progressive disease (PD) and those
without PD, stages III and IV disease, or recurrence. The
survival time (progression-free survival [PFS] and overall
survival [OS]) and clinical factors (age, gender, and Eastern
Cooperative Oncology Group [ECOG] performance status166 cells/4 mL Range (2–1195 cells/4 mL) Total Pa
lls/4 mL <166 cells/4 mL
high CEClow
2 25 37
10 18 (49%) 0.17
15 19 (51%)
17 24 (65%) 0.72
8 13 (35%)
11 14 (38%) 0.59
12 20 (54%)
2 3 (8%)
18 23 (62%) 0.09
4 10 (27%)
3 4 (11%)
12 17 (46%) >0.9
9 14 (38%)
4 6 (16%)
5 8 (22%) >0.9
20 29 (78%)
3 10 (27%) <0.01
22 27 (73%)




2 4 (11%) <0.05
18 22 (59%)
5 11 (30%)
12 18 (49%) 1
2 2 (5%)
11 17 (46%)
gy Group; CA19-9 = carbohydrate antigen 19–9; CRP =C-reactive protein.
Figure 1 Kaplan-Meier curves for (A) progression-free survival with CEC counts, (B) progression-free survival with IL-6 levels, (C)
progression-free survival with IL-8 levels, (D) progression-free survival with IL-10 levels, (E) progression-free survival with VEGF levels,
(F) progression-free survival with PDGF-BB levels, (G) progression-free survival with HGF levels, and (H) progression-free survival with
SDF-1 alpha levels. The cut-off points for the angiogenic factors were determined to be equal to or greater than these mean levels.
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using the Cox proportional hazards model. The survival
curves for PFS and OS were estimated using the Kaplan-
Meier method. Kaplan-Meier curves were used only to de-
termine the trends of the associations between the mole-
cules and PFS/OS, as any determination of the optimal
cutoff point for the molecules relative to PFS/OS was
beyond the scope of the present study. All statistical
analyses were performed using IBM SPSS Statistics 18
(IBM Corporation, Somers, NY, USA).
Results
Patient characteristics
A total of 37 patients with pancreatic carcinoma were
prospectively enrolled in this study. Fourteen of these
patients (38%) presented with locally advanced pancre-
atic carcinoma, 20 patients (54%) presented with metas-
tases, and 3 patients (8%) were enrolled following
recurrence after surgery. Twenty-three patients (62%)
had ECOG PS0, 10 patients (27%) had ECOG PS1, and 4
patients (11%) had ECOG PS2. Histologically, 14
patients (38%) had poorly differentiated adenocarcin-
oma, 14 patients (38%) had moderately differentiated
adenocarcinoma, 1 patient (2%) had an adenosquamous
tumor, and 8 patients (22%) had cytological adenocarcin-
oma. No patient experienced a complete response to
treatment. Four patients (11%) exhibited a partial re-
sponse (PR) rate to treatment (11%), stable disease (SD)
was observed in 22 patients (59%), and PD was observed
in 11 patients (30%). Second-line therapy was adminis-
tered to 20 patients (54%), whereby 18 patients (49%)
received S-1 monotherapy and 2 patients (5%) received
oxaliplatin and S-1 combination therapy (Table 1).
Baseline levels of CECs and angiogenic factors
The mean CEC level found in the pancreatic carcinoma
patients was 166 cells/4 mL (range: 2–1195 cells/4 mL)
while the median CEC level was 66 cells/4 mL. These
CEC levels were higher than those of randomly-selected
healthy volunteers (P< 0.01), as previously reported
(n = 53, mean ± SD= 46.2 ± 86.3 cells/4 mL) [9]. In this
study, the cut-off point of CEChigh was determined to be
equal to or greater than 166 cells/4 mL while that of
CEClow was lower than 166 cells/4 mL. CEChigh was
significantly associated with high levels of C-reactive
protein (CRP) (over 1.0 mg/dL; P< 0.01). The median
PFS was 64 days (95% confidence interval [CI], 45–83)
in the CEChigh group, while that in the CEClow group
was 150 days (95% CI, 130–170; log-rank test; P= 0.008;
Figure 1A). The median OS was 143 days (95% CI,
53–233) in the CEChigh group and 297 days (95% CI,
240–354) in the CEClow group (log-rank test; P< 0.001;
Figure 2A). Univariate analysis of CEC levels and
clinical factors for OS was performed using the Coxproportional hazard model. The hazard ratio (HR) for
CEC levels (CEChigh versus CEClow) was 5.18 (95% CI,
2.23–12.03; P< 0.001).
The mean levels of IL-6, IL-8, IL-10, PDGF-BB,
VEGF, HGF, and SDF-1 alpha were found to be
19.3 pg/mL, 11.3 pg/mL, 7.82 pg/mL, 1127.5 pg/mL,
44.1 pg/mL, 471.3 pg/mL, and 110.6 pg/mL, respect-
ively. The cut-off points for the angiogenic factors were
determined to be equal to or greater than these mean
levels, and the median PFS in HGFlow was longer than
the HGFhigh group (P= 0.001; Figure 1G). However,
other factors were not found to have statistical signifi-
cance with regard to PFS. The median OS was longer in
the case of IL-10 (112 days [95% CI, 50–173] in IL-10high
vs. 264 days [95% CI, 204–324] IL-10low, log-rank test:
P= 0.003; Figure 2d) and HGF (150 days [95% CI, 65–
234] in HGFhigh vs. 291 days [95% CI, 223–359] in
HGFlow, log-rank test: P= 0.01; Figure 2G).
Among the clinical factors that were examined in this
study, a poor PS (PS 1 and 2), advanced stage (stage IV
and recurrence), and high levels of IL-10, HGF, and CRP
were significantly correlated with poor OS in univariate
cox analysis, with HRs of 2.72 (95% CI, 1.29–5.70;
P= 0.008), 2.21 (95% CI, 1.03–4.71; P= 0.04), 5.05 (95%
CI, 1.55–16.39; P= 0.007), 2.52 (95% CI, 1.22–5.21;
P= 0.01), and 2.49 (95% CI, 1.14–5.42; P= 0.02), respect-
ively. In a multivariate Cox analysis model that included
clinical stage, PS, CRP levels, CEC levels, IL-10 levels,
and HGF levels, the number of CECs detected remained
statistically stable at 0.05. The resulting HRs were
2.04 (95% CI, 0.78–5.35; P=0.15), 2.58 (95% CI, 0.98–6.76;
P> 0.05), 2.04 (95% CI, 0.62–6.76; P=0.24), 5.14 (95% CI,
1.83–14.45, P=0.002), 5.26 (95% CI, 1.26–22.22; P=0.02)
and 1.34 (95% CI, 0.46–3.91; P=0.59), respectively
(Table 2).
Changes in CEC number during treatment
The number of CECs was analyzed in 22 of the 37
patients at 28 ± 7 days after the start of gemcitabine
therapy. The mean number of CECs detected in these
patients after 28 ± 7 days was 133 cells/4 mL (range:
15–664 cells/4 mL), while the median number of CECs
was 68 cells/4 mL. The absolute counts of CECs did
not change significantly between day 1 and day 28 ± 7
of treatment (Mann–Whitney test, P = 0.11). Further-
more, a change in CEC counts from baseline to after
28± 7 days of treatment was not statistically associated
with tumor response (Mann–Whitney test, P> 0.05,
Figure 3).
Association between CEC number and blood angiogenic
factors
The numbers of CECs were compared between non-
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Figure 2 Kaplan-Meier curves for (A) overall survival with CEC counts, (B) overall survival with IL-6 levels, (C) overall survival with IL-8
levels, (D) overall survival with IL-10 levels, (E) overall survival with VEGF levels, (F) overall survival with PDGF-BB levels, (G) overall
survival with HGF levels, and (H) overall survival with SDF-1 alpha levels. The cut-off points for the angiogenic factors were determined to
be equal to or greater than these mean levels.
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(P< 0.01), and IL-10 (P= 0.03) were found to be signifi-
cantly higher among patients with PD than among
those with PR or SD. The blood concentrations of HGF
(P< 0.001), IL-6 (P< 0.01), and IL-8 (P< 0.001) were also
significantly higher among patients with clinical stage IV
disease and recurrence than among those with stage III
disease. When the association between CEC number and
the expression of other angiogenic factors was examined,
the number of CECs was found to correlate positively
with the levels of VEGF (r= 0.34, P=0.04), HGF (r= 0.37,
P=0.02), IL-8 (r = 0.38, P=0.02), and IL-10 (r = 0.45,
P=0.006), suggesting that the number of CECs is related
to the expression of these markers (Table 3).
Discussions
In most cases, CECs are apoptotic or necrotic cells that
are released into circulation as a byproduct of vascular
turnover. In some cancer patients, the level of CECs is
significantly higher than that of healthy individuals, and
this increased level has been identified as a surrogateTable 2 Univariate and multivariate Cox analyses of prognosi
Univariate analysis
Age: Over 70 vs. Below 70
Sex: Male vs. Female
Stage: IV + Recurrence vs. III
ECOG PS: 2 + 1 vs. 0
Pancreatic tumor location: Head vs. Others
CA19-9 (cut-off: 10,000 U/mL): CA19-9high vs. CA19-9low
CRP level (cut-off: 1.0 mg/dL): CRPhigh vs. CRPlow
Histology: Poorly differentiated vs. Others
Second line therapy: Yes vs. No
CEC level (cut-off: 166 cells/4 mL): CEChigh vs. CEClow
IL-6 (cut-off: 19.3 pg/mL): IL-6high vs. IL-6low
IL-8 (cut-off: 11.3 pg/mL): IL-8high vs. IL-8low
IL-10 (cut-off: 7.82 pg/mL): IL-10high vs. IL-10low
VEGF (cut-off: 44.1 pg/mL): VEGFhigh vs. VEGFlow
PDGF-BB (cut-off: 1127.5 pg/mL): PDGF-BBhigh vs. PDGF-BBlow
HGF (cut-off: 471.3 pg/mL): HGFhigh vs. HGFlow
SDF-1 alpha (cut-off: 110.6 pg/mL): SDF-1 alphahigh vs. SDF-1 alphalow
Multivariate analysis
Stage: IV + Recurrence vs. III
ECOG PS: 2 + 1 vs. 0
CRP level (cut-off: 1.0 mg/dL): CRPhigh vs. CRPlow
CEC level (cut-off: 166 cells/4 mL): CEChigh vs. CEClow
IL-10 (cut-off: 7.82 pg/mL): IL-10high vs. IL-10low
HGF (cut-off: 471.3 pg/mL): HGFhigh vs. HGFlow
Abbreviations: HR = hazard ratio; CI = confidence interval; ECOG PS = Eastern Cooper
IL = interleukin; PDGF-BB = platelet-derived growth factor-B chain; VEGF = vascular e
= carbohydrate antigen 19–9; CRP =C-reactive protein; CEA= carcinoembryonic antimarker of angiogenesis and anti-angiogenic drug activity
[10,11]. The present study has shown that baseline CEC
levels are markedly higher among pancreatic carcinoma
patients than in healthy individuals. Our results also
support the hypothesis that CEC levels are associated
with clinical outcome in pancreatic carcinoma patients
undergoing gemcitabine chemotherapy, and may be a
prognostic factor for this disease. A previous study
found that the baseline level of CECs, identified as
CD45-CD31+CD34+ by flow cytometry, was inversely
associated with OS in patients who had gemcitabine-
refractory metastatic pancreatic carcinoma and were
treated with bevacizumab plus erlotinib [12]. CEC
(CD45-CD31+CD146+) detection by flow cytometry
requires careful discrimination between blood cell popu-
lations with overlapping phenotypes showing hallmarks
of T cells (CD45-CD31-CD146+) and platelets (CD45-
CD31highCD146-). These cells populations show distinct
regulation during cancer therapy, and their concomitant
analysis may offer extended prognostic and predictive
information [13].s
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Figure 3 Waterfall plot showing the changes in CEC counts and tumor response in patients without progressive disease (PD) (those
with partial response [PR] or stable disease [SD]) and patients with PD, after 28 ± 7 days of gemcitabine treatment.
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well as the levels of HGF, IL-6, and IL-10, which are
associated with gemcitabine resistance or stemness, to
be significantly higher among PD patients. Univariate
Cox model analysis further demonstrated that PS, clin-
ical stage, CRP levels, and CEC levels are all associated
with the survival of pancreatic carcinoma patients, while
multivariate Cox analysis showed that CEC and IL-10
levels are strongly associated with survival.Table 3 Association between CECs and other factors
Mean± SD
CEC (cells/4 mL) 166.2 ± 228.9
IL-6 (pg/mL) 19.3 ± 52.4
IL-8 (pg/mL) 11.3 ± 10.1
IL-10 (pg/mL) 7.82 ± 26.9
VEGF (pg/mL) 44.1 ± 38.8
PDGF-BB (pg/mL) 1,127.5 ± 941.5
HGF (pg/mL) 471.3 ± 249.0
SDF-1alpha (pg/mL) 110.6 ± 43.7
CRP (mg/dL) 1.9 ± 3.9
CA19-9 (U/mL) 18,229.1 ± 55,377.8
CEA (ng/mL) 18.3 ± 51.0
Abbreviations: CEC= Circulating endothelial cell; IL = interleukin; PDGF-BB = platelet-
HGF = hepatocyte growth factor; CA19-9 = carbohydrate antigen 19–9; CRP =C-reactThe number of CECs detectable in individuals has
previously been found to be associated with the plasma
levels of VCAM-1 and VEGF in cancer patients [14]
[15]. Our findings further show that, in addition to
VEGF, CEC levels are strongly associated with the
expression levels of IL-8, IL-10, and HGF in pancreatic
carcinoma patients. These molecules, among others,
play important roles in tumor biology and have been












derived growth factor-B chain; VEGF = vascular endothelial growth factor;
ive protein; CEA = carcinoembryonic antigen.
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controlling cell migration, particularly in leukocytes,
during inflammation and the immune response. Chemo-
kines are also important in tumor biology as they influ-
ence tumor growth, invasion, metastasis, and
angiogenesis. For instance, VEGF, HGF and IL-8 signifi-
cantly stimulate the proliferation, migration, and inva-
sion of cancer cells. CEC are shed from vessels and this
process may be amplified by an aberrant vascular turn-
over/remodeling associated with high local levels of
VEGF required for CEC survival [16]. The chemokine
SDF-1 has likewise been found to enhance the produc-
tion of IL-8 by pancreatic cells in a paracrine manner
[17]. Although our results did not indicate that SDF-1
levels were associated with CEC or IL-8 levels in the
pancreatic cancer patients examined, it is likely that sev-
eral of the proangiogenic factors examined in this study
interact with each other to promote vascular turnover
and remodeling, thereby leading to a higher number of
CECs in the peripheral blood of cancer patients.
Drugs targeting angiogenesis, such as those that inhibit
the VEGF pathway, have had a major impact in the treat-
ment of many types of cancer. The VEGF pathway is also
an independent prognostic factor for patient survival in
pancreatic carcinoma. Although preclinical models have
suggested that VEGF-VEGF receptor inhibitors would be
effective in the treatment of pancreatic carcinoma,
patients who received bevacizumab and axitinib therapy
in addition to gemcitabine have not shown a survival ad-
vantage when compared to those treated with gemcitabine
alone [6,18]. These results add to the increasing evidence
that suggests that targeting VEGF signaling is an ineffect-
ive strategy in the treatment of pancreatic carcinoma.
However, many antiangiogenic therapies modulate the ex-
pression levels of proangiogenic factors [19], and many
factors are associated with tumor angiogenesis. Therefore,
there are a variety of potential therapeutic targets that
may be exploited in order to target angiogenesis, poten-
tially including those examined in this study.
In advanced non-small cell lung cancer (NSCLC),
patients with higher baseline CEC counts have PR/SD and
longer PFS. It has also previously been reported that the
elevated CEC numbers exhibited in NSCLC patients de-
crease following treatment with carboplatin in combin-
ation with paclitaxel [9]. Paclitaxel and docetaxel are
categorized as mitotic spindle agents with potent antian-
giogenic properties [20-22]. Therefore, it seems that the
baseline CEC count is a promising predictor of clinical re-
sponse to the carboplatin plus paclitaxel regimen, as well
as of survival. However, although several other clinical
studies that have examined CECs have also found chemo-
therapy to be associated with either an increase or de-
crease in CEC number [23,24], no association was
detected between gemcitabine treatment and CECnumber in the pancreatic carcinoma patients in our study.
Although gemcitabine has anti-angiogenic properties,
higher baseline CEC levels were associated with PD in
pancreatic carcinoma patients receiving gemcitabine ther-
apy, and patients with high CEC counts exhibited poor
clinical condition. It is therefore likely that the tumor type,
anti-cancer drugs being administered, and the amount of
time between the start of treatment and the time when
CEC counts are obtained influence the number of CECs
detected in cancer patients after treatment. In this study,
we measured CEC levels before starting chemotherapy
and at 28± 7 days after starting chemotherapy, the time of
sampling might influence the changes of CEC level. More-
over, the diversity in literature regarding CEC up-or
down-regulation during cancer therapy and the associated
prognostic and predictive evidence might in part be
explained by a differential focus on or by the lack of dis-
crimination between these cell populations [13].
Conclusions
Although the number of patients examined in this study
was small, and patients were recruited prospectively, this
study, along with others, has shown the clinical import-
ance of CEC number as a prognostic factor in advanced
pancreatic carcinoma treated with gemcitabine chemo-
therapy, whereby high CEC counts are associated with
poor prognosis. This study also found that elevated CEC
counts are associated with the high expression levels of
several chemokines and proangiogenic factors involved in
the regulation of tumor immunological and angiogenic
factors. Although this correlation between blood para-
meters is not proof of a causal relationship, these factors
may provide viable therapeutic targets for the treatment
of pancreatic carcinoma in the future. Further studies in a
larger population will be required to confirm our findings.
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